Display options
Cite
Roupakia E, Chavdoula E, Karpathiou G, et al. Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174302.
Roupakia, E., Chavdoula, E., Karpathiou, G., Vatsellas, G., Chatzopoulos, D., Mela, A., Gillette, J. M., Kriegsmann, K., Kriegsmann, M., Batistatou, A., Goussia, A., Marcu, K. B., Karteris, E., Klinakis, A., & Kolettas, E. (2021). Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. Cancers, 13(17), . https://doi.org/10.3390/cancers13174302
Roupakia, Eugenia, et al. "Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174302
Roupakia E, Chavdoula E, Karpathiou G, Vatsellas G, Chatzopoulos D, Mela A, Gillette JM, Kriegsmann K, Kriegsmann M, Batistatou A, Goussia A, Marcu KB, Karteris E, Klinakis A, Kolettas E. Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. Cancers (Basel). 2021 Aug 26;13(17). doi: 10.3390/cancers13174302. PMID: 34503110; PMCID: PMC8428346.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Aug 26;13(17). doi: 10.3390/cancers13174302.

Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition.

Cancers

Eugenia Roupakia, Evangelia Chavdoula, Georgia Karpathiou, Giannis Vatsellas, Dimitrios Chatzopoulos, Angeliki Mela, Jennifer M Gillette, Katharina Kriegsmann, Mark Kriegsmann, Anna Batistatou, Anna Goussia, Kenneth B Marcu, Emmanouil Karteris, Apostolos Klinakis, Evangelos Kolettas

Affiliations

  1. Laboratory of Biology, School of Medicine, Faculty of Health Sciences, Institute of Biosciences, University Research Centre, University of Ioannina, University Campus, 45110 Ioannina, Greece.
  2. Biomedical Research Division, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, University of Ioannina Campus, 45115 Ioannina, Greece.
  3. Biomedical Research Foundation, Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.
  4. Laboratory of Pathology, School of Medicine, Faculty of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
  5. Department of Pathology and Cell Biology Columbia University Medical Center, Irving Comprehensive Cancer Research Center, Columbia University, New York, NY 10032, USA.
  6. Department of Pathology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
  7. Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  8. Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  9. Department of Biochemistry and Cell Biology, Microbiology and Pathology, Stony Brook University, New York, NY 11794, USA.
  10. Division of Biosciences, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, Middlesex, London UB8 PH, UK.

PMID: 34503110 PMCID: PMC8428346 DOI: 10.3390/cancers13174302

Abstract

BACKGROUND: The development of non-small cell lung cancer (NSCLC) involves the progressive accumulation of genetic and epigenetic changes. These include somatic oncogenic

METHODS: Human NSCLC cells were used to knock-down RelA/p65 (RelA/p65

RESULTS: RelA/p65

CONCLUSIONS: Canonical NF-κB signalling promotes NSCLC, in part, by downregulating the metastasis suppressor CD82/KAI1 which inhibits cell migration, EMT and tumour growth.

Keywords: CD82; EMT; NF-κB RelA/p65; RNA-seq; cell migration; human NSCLC models; integrin signalling

References

  1. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  2. Cancer Converg. 2017;1(1):2 - PubMed
  3. J Cell Biol. 2011 Dec 26;195(7):1123-40 - PubMed
  4. N Engl J Med. 2008 Sep 25;359(13):1367-80 - PubMed
  5. Cancer Metastasis Rev. 2015 Dec;34(4):619-33 - PubMed
  6. Nature. 2009 Nov 5;462(7269):104-7 - PubMed
  7. Mech Ageing Dev. 2009 Jul;130(7):409-19 - PubMed
  8. Cell Signal. 2018 Dec;52:83-94 - PubMed
  9. Cancer Cell. 2019 Mar 18;35(3):347-367 - PubMed
  10. Curr Protoc Pharmacol. 2012 Dec;Chapter 14:Unit 14.22 - PubMed
  11. J Cell Physiol. 2010 Nov;225(3):682-91 - PubMed
  12. Nat Cell Biol. 2006 Jun;8(6):631-9 - PubMed
  13. Cancer Res. 2010 May 1;70(9):3537-46 - PubMed
  14. Cancer Res. 2020 Oct 1;80(19):4025-4036 - PubMed
  15. Genes Dev. 2012 Feb 1;26(3):203-34 - PubMed
  16. Oncogene. 2012 Mar 1;31(9):1143-54 - PubMed
  17. Cell Rep. 2015 Feb 10;10(5):726-739 - PubMed
  18. Trends Mol Med. 2005 Dec;11(12):563-70 - PubMed
  19. Oncogene. 2004 Aug 19;23(37):6304-15 - PubMed
  20. Science. 1995 May 12;268(5212):884-6 - PubMed
  21. Int J Biochem Cell Biol. 2016 Aug;77(Pt A):68-71 - PubMed
  22. Cancer Cell. 2009 May 5;15(5):416-28 - PubMed
  23. Annu Rev Pathol. 2018 Jan 24;13:395-412 - PubMed
  24. Appl Immunohistochem Mol Morphol. 2017 Oct;25(9):e74-e79 - PubMed
  25. Mol Cell. 2004 Mar 26;13(6):853-65 - PubMed
  26. Nat Rev Cancer. 2009 Jan;9(1):40-55 - PubMed
  27. Life Sci Alliance. 2019 Dec 2;2(6): - PubMed
  28. Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11 - PubMed
  29. J Cell Physiol. 2009 Jan;218(1):215-27 - PubMed
  30. PLoS One. 2015 Jul 06;10(7):e0132527 - PubMed
  31. Nat Rev Cancer. 2012 Jan 19;12(2):121-32 - PubMed
  32. J Neurosci. 2013 May 1;33(18):7952-60 - PubMed
  33. J Cell Biol. 2010 Sep 20;190(6):1079-91 - PubMed
  34. J Clin Invest. 2011 Oct;121(10):4095-105 - PubMed
  35. Oncogene. 2016 Aug 4;35(31):4132-40 - PubMed
  36. Oncotarget. 2017 Jan 24;8(4):6496-6512 - PubMed
  37. Exp Gerontol. 2017 Oct 1;96:110-122 - PubMed
  38. Cancer Cell. 2010 Jan 19;17(1):89-97 - PubMed
  39. Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84 - PubMed
  40. Int J Biochem Cell Biol. 2012 May;44(5):703-8 - PubMed
  41. Oncogene. 2016 Feb 18;35(7):919-28 - PubMed
  42. Nature. 2008 Oct 23;455(7216):1069-75 - PubMed
  43. Nature. 2018 Jan 24;553(7689):446-454 - PubMed
  44. Nat Med. 2006 Aug;12(8):933-8 - PubMed
  45. Cell. 2002 Jul 12;110(1):55-67 - PubMed
  46. PLoS One. 2013 Jul 30;8(7):e68597 - PubMed
  47. Nature. 2021 Jul;595(7865):114-119 - PubMed
  48. Cancer Res. 2012 Mar 1;72(5):1290-300 - PubMed
  49. Clin Chest Med. 2020 Mar;41(1):25-38 - PubMed
  50. Mol Cancer. 2019 May 22;18(1):98 - PubMed
  51. Cancer Res. 2003 May 15;63(10):2665-74 - PubMed
  52. J Cell Biochem. 2008 Jun 1;104(3):733-44 - PubMed
  53. Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):4910-5 - PubMed
  54. Nat Rev Clin Oncol. 2021 Jan;18(1):35-55 - PubMed
  55. Nature. 2011 Mar 24;471(7339):523-6 - PubMed
  56. Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):255-60 - PubMed
  57. J Pathol. 2011 Jan;223(1):4-14 - PubMed
  58. Oncotarget. 2017 Mar 21;8(12):19310-19322 - PubMed
  59. Cell. 2012 Mar 30;149(1):246-246.e1 - PubMed
  60. Immunity. 2020 May 19;52(5):731-733 - PubMed
  61. Cancer Res. 2007 Feb 15;67(4):1744-9 - PubMed
  62. Nat Rev Microbiol. 2016 Aug;14(8):523-34 - PubMed
  63. J Biol Chem. 2001 May 25;276(21):18579-90 - PubMed
  64. Nat Med. 2013 Nov;19(11):1438-49 - PubMed
  65. Cancers (Basel). 2018 Jul 27;10(8): - PubMed
  66. Science. 2020 Mar 27;367(6485):1444-1448 - PubMed
  67. Cancer Res. 2004 Oct 15;64(20):7455-63 - PubMed
  68. Nat Rev Immunol. 2018 May;18(5):309-324 - PubMed
  69. Oncogene. 2017 Mar;36(11):1461-1473 - PubMed
  70. Cancer Cell. 2020 Aug 10;38(2):212-228.e13 - PubMed
  71. Carcinogenesis. 2020 Dec 31;41(12):1671-1681 - PubMed
  72. Nat Cell Biol. 2012 Feb 12;14(3):257-65 - PubMed
  73. FEBS Lett. 2011 Oct 20;585(20):3166-73 - PubMed
  74. J Thorac Oncol. 2012 Jul;7(7):1086-90 - PubMed
  75. Cells. 2019 Sep 25;8(10): - PubMed
  76. Cell. 2013 Jan 17;152(1-2):25-38 - PubMed
  77. Mol Biol Cell. 2014 May;25(10):1560-73 - PubMed
  78. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 - PubMed
  79. Nature. 2005 Apr 14;434(7035):921-6 - PubMed
  80. Nat Med. 2015 May;21(5):431-9 - PubMed
  81. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  82. J Immunother Cancer. 2020 Aug;8(2): - PubMed
  83. Cell Signal. 2012 Nov;24(11):2007-23 - PubMed
  84. Cancer Cell. 2012 Mar 20;21(3):448.e2 - PubMed
  85. Immunity. 2019 May 21;50(5):1317-1334.e10 - PubMed
  86. Nature. 2021 May;593(7860):564-569 - PubMed
  87. Nat Med. 2020 Oct;26(10):1636-1643 - PubMed
  88. Cell Rep. 2015 Apr 7;11(1):98-110 - PubMed
  89. Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62 - PubMed
  90. Cancer Res. 2015 May 1;75(9):1789-800 - PubMed
  91. Mol Cell. 2014 Jan 23;53(2):193-208 - PubMed
  92. Cancer Cell. 2020 Aug 10;38(2):229-246.e13 - PubMed
  93. Biochem Biophys Res Commun. 2000 Dec 29;279(3):744-50 - PubMed

Publication Types

Grant support